Amgen (AMGN) Common Equity (2009 - 2026)

Amgen's Common Equity history runs 18 years deep, the most recent figure standing at $9.2 billion for Q1 2026.

• In Q1 2026, Common Equity rose 48.06% year-over-year to $9.2 billion; the TTM figure through Mar 2026 stood at $9.2 billion (up 48.06% YoY), while the FY2025 annual figure was $8.7 billion, up 47.32% from the prior year.
• Common Equity was $9.2 billion for Q1 2026 at Amgen, up from $8.7 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $9.6 billion in Q3 2025 to a low of $916.0 million in Q1 2022.
• Historically, Common Equity has averaged $6.0 billion across 5 years, with a median of $6.2 billion in 2025.
• The sharpest annual moves came in 2022 and 2023: Common Equity slumped 90.19% in 2022, then soared 483.84% in 2023.
• A 5-year view of Common Equity shows it stood at $3.7 billion in 2022, then soared by 70.23% to $6.2 billion in 2023, then decreased by 5.7% to $5.9 billion in 2024, then soared by 47.32% to $8.7 billion in 2025, then gained by 6.14% to $9.2 billion in 2026.
• The last three Common Equity figures came in at $9.2 billion (Q1 2026), $8.7 billion (Q4 2025), and $9.6 billion (Q3 2025), per Business Quant data.